As aggregation of mHTT or nuclear pore proteins was not observed in our striatal neurons, we decided to take a different approach and lowered total HTT expression using antisense oligonucleotides (ASOs; Takeda Pharmaceuticals) delivered via nanoparticles in order to investigate whether this could normalize gene or protein expression, or restore the N/C ratios of RAN, RANGAP1 and lamin-B1 in human HD PSC-derived striatal neurons. The gene discussed is RAN; the disease is Huntington disease.